Transparency
Who built this
Aesthetic medicine is regulated from three directions at once, by bodies that do not talk to each other. A state legislature decides who may inject and under whose supervision. The FDA decides what may be compounded, and quietly flips that answer every time a drug moves on or off the shortage list. The FTC decides how a result may be advertised. A practice can be fully compliant on Monday and out of compliance on Tuesday because of a document none of its staff had any reason to read.
Every other regulated industry has someone watching. Hospital systems have compliance departments. Pharmacies have subscription services. Cash-pay aesthetics — one of the fastest-growing corners of American medicine — has trade-association newsletters, a Facebook group, and whatever the injector down the street heard. That gap is the whole reason this exists.
Scanned 485 · 119 material changes26 states on record + federal11 feeds behind these itemslatest Sep 21, 2026sources last scanned Sep 28, 2026
Not a first attempt
MedSpaRadar is built and operated by CLV Media, LLC (Charlotte, NC 28277), and it runs on the same monitoring engine as our sibling product, CLV Intelligence ↗, which tracks Medicare coverage policy for healthcare providers. The scrapers, the change-hash diffing, the source-health heartbeat, the human approval gate — all of it was built, broken, and hardened somewhere else first, against a regulator with far less patience for error.
That inheritance is the honest answer to “why should I trust a product I have never heard of?” The brand is new. The machinery is not, and the rules it operates under were written the expensive way.
Underneath both products sits a monitoring layer that reads primary sources directly. For MedSpaRadar it polls 43 of them every 2 hours — 14 federal and 30 state — and stores every item with the publisher’s own payload and the moment we first saw it, so a claim about what was published, and when, can be checked rather than taken on trust. That includes the Federal Register’s public-inspection desk, where documents are filed before their publication date; the amendment log for the regulatory text itself, rather than a page describing it; federal court dockets, where a dispute becomes visible before any regulator writes about it; and the state medical, osteopathic, pharmacy and nursing boards — Texas and Florida among them — which decide who may supervise and who may inject.
The rules we work under
These are engineering constraints, not marketing promises — each one is enforced in code, and most exist because something went wrong first.
A human approves anything that matters.
Every rule change reaching the feed or an inbox was read by a person first. The only exception is high-volume background exhaust from 2 capped sources, which cannot email anyone by construction.
Publishing and emailing are separate decisions.
Approving an item makes it public. It does not send it. Interrupting someone requires three more things to be true at once, and most items never clear them.
Every item links its primary source.
The 11 feeds behind the alert pipeline, and the 44 primary sources monitored on top of them, are government publications, state public records, or licensed legislative data — every one named in full with the endpoint we read. Nothing is paraphrased from a competitor or generated.
Watching a source is not the same as telling you about it.
We monitor far more than we publish, and that is deliberate. A source entering the sweep widens what we can see; it does not create an alert. What reaches the feed or an inbox is decided afterwards, by the same review, and most of what we collect never gets there.
A gap is shown as a gap.
Where a source gives no date, no number, or no answer, you get an em dash. We do not estimate, and we do not fill a hole with something plausible.
Monitoring, not advice.
We tell you what changed, what it appears to require, and where to read it yourself. Anything consequential belongs in front of your own counsel.
The full scoring and routing rules are on methodology — including the thresholds, and the two cases where our own classifier was wrong and we built a gate around it.
Check us
Nothing on this page asks for the benefit of the doubt. Every source we poll is listed with its endpoint, the pipeline’s last confirmed scan is on a public page, and the entire published corpus is readable without an account. If something here does not hold up, we would rather hear it: support@medsparadar.com.